Market Cap | 1.18B | P/E | - | EPS this Y | 16.00% | Ern Qtrly Grth | - |
Income | -192.65M | Forward P/E | -4.99 | EPS next Y | -12.60% | 50D Avg Chg | 3.00% |
Sales | 20.65M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | 2.32 | EPS next 5Y | - | 52W High Chg | -56.00% |
Recommedations | 1.80 | Quick Ratio | 14.34 | Shares Outstanding | 84.62M | 52W Low Chg | 47.00% |
Insider Own | 1.78% | ROA | -21.51% | Shares Float | 62.40M | Beta | 1.84 |
Inst Own | 91.56% | ROE | -38.10% | Shares Shorted/Prior | 15.87M/16.25M | Price | 19.12 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 604,911 | Target Price | 25.13 |
Oper. Margin | -879.24% | Earnings Date | - | Volume | 479,433 | Change | -1.54% |
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Canaccord Genuity | Buy | Aug 12, 24 |
HC Wainwright & Co. | Buy | Aug 12, 24 |
RBC Capital | Outperform | Aug 9, 24 |
HC Wainwright & Co. | Buy | May 9, 24 |
Stifel | Buy | Apr 3, 24 |
RBC Capital | Outperform | Feb 28, 24 |
Cantor Fitzgerald | Neutral | Sep 13, 23 |
Cantor Fitzgerald | Neutral | Aug 29, 23 |
Guggenheim | Buy | Aug 15, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Bellinger Andrew | CSO & CMO CSO & CMO | Dec 14 | Option | 2.87 | 36,000 | 103,320 | 42,629 | 12/16/22 |
Bellinger Andrew | CSO & CMO CSO & CMO | Dec 01 | Sell | 22.95 | 865 | 19,852 | 6,629 | 12/02/22 |
Yeshwant Krishna | Director Director | Nov 04 | Sell | 32 | 48,583 | 1,554,656 | 4,260,047 | 11/08/22 |
GV 2017 GP, L.L.C. | Other Other | Nov 04 | Sell | 32 | 97,166 | 3,109,312 | 4,260,047 | 11/08/22 |
GV 2017 GP, L.L.C. | Other Other | Nov 02 | Sell | 34.52 | 156,440 | 5,400,309 | 4,308,630 | 11/04/22 |
Yeshwant Krishna | Director Director | Oct 31 | Sell | 38.69 | 85,659 | 3,314,147 | 4,386,850 | 11/02/22 |
Ashe Andrew D. | See Remarks See Remarks | Aug 25 | Option | 1.91 | 95,787 | 182,953 | 266,509 | 08/29/22 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Aug 10 | Option | 1.39 | 50,000 | 69,500 | 367,839 | 08/11/22 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Aug 10 | Sell | 29.9 | 50,000 | 1,495,000 | 317,839 | 08/11/22 |
Bellinger Andrew | CSO & CMO CSO & CMO | Jul 20 | Option | 1.39 | 20,000 | 27,800 | 26,629 | 07/22/22 |
Bellinger Andrew | CSO & CMO CSO & CMO | Jul 20 | Sell | 34.9 | 20,000 | 698,000 | 6,629 | 07/22/22 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Jul 19 | Option | 1.39 | 50,000 | 69,500 | 367,839 | 07/21/22 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Jul 19 | Sell | 29.9 | 50,000 | 1,495,000 | 317,839 | 07/21/22 |
Bellinger Andrew | CSO & CMO CSO & CMO | Jul 13 | Option | 1.48 | 10,000 | 14,800 | 16,629 | 07/15/22 |
Bellinger Andrew | CSO & CMO CSO & CMO | Jul 13 | Sell | 24.9 | 10,000 | 249,000 | 6,629 | 07/15/22 |
FMR LLC | 10% Owner 10% Owner | Jul 12 | Sell | 21.01 | 163,000 | 3,424,630 | 570,729 | 07/14/22 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Mar 18 | Option | 2.87 | 69,674 | 199,964 | 477,525 | 03/22/22 |
ADELMAN BURT A | Director Director | Mar 15 | Buy | 21.3838 | 4,000 | 85,535 | 8,700 | 03/17/22 |
FMR LLC | 10% Owner 10% Owner | Mar 09 | Sell | 29.01 | 3,971 | 115,199 | 825,723 | 03/11/22 |
FMR LLC | 10% Owner 10% Owner | Feb 09 | Sell | 29.46 | 13,190 | 388,577 | 829,694 | 02/11/22 |
FMR LLC | 10% Owner 10% Owner | Feb 01 | Sell | 29.04 | 35,574 | 1,033,069 | 842,884 | 02/03/22 |
FMR LLC | 10% Owner 10% Owner | Jan 26 | Sell | 30.41 | 158,836 | 4,830,203 | 878,458 | 01/28/22 |
Bellinger Andrew | Chief Scientific Off.. Chief Scientific Officer | Dec 22 | Option | 1.48 | 15,000 | 22,200 | 20,000 | 12/27/21 |
Bellinger Andrew | Chief Scientific Off.. Chief Scientific Officer | Dec 22 | Sell | 38.47 | 15,000 | 577,050 | 5,000 | 12/27/21 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Dec 22 | Option | 1.39 | 114,000 | 158,460 | 463,536 | 12/27/21 |
Kathiresan Sekar | Chief Executive Offi.. Chief Executive Officer | Dec 22 | Sell | 38.89 | 114,000 | 4,433,460 | 406,536 | 12/27/21 |